5α-還元酵素欠損症の世界市場レポート 2025年

5α-還元酵素欠損症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.7％で21億7,000万米ドルに成長します。予測期間の成長は、治療法の革新、遺伝子研究の進歩、精密医療、世界ヘルスイニシアチブ、遺伝子治療の統合に起因しています。予測期間の主な動向には、治療オプションの進歩、診断イノベーション、患者中心のアプローチ、規制状況、市場アクセス、手頃な価格などが含まれます。

ゲノミクスにおける研究開発の増加は、5α-還元酵素欠損症市場の成長に大きく寄与しています。遺伝子と環境の相互作用を含む個人の全ゲノムの包括的な研究を含むゲノミクスは、5α-還元酵素欠損症の診断において、その症状の原因となる特定の遺伝子変異をピンポイントで特定する極めて重要なツールとして機能します。その結果、ゲノミクスにおける研究開発活動の急増は、この疾患の発見だけでなく、治療においても重要な役割を果たすことになります。世界保健機関（WHO）が2022年7月に発表した報告書「Accelerating Access to Genomics for Global Health」に詳述されているように、2021年3月から2022年1月にかけて、ゲノムサーベイランスを実施できる国の割合が54％から68％に急増しました。そのため、ゲノミクスにおける研究開発の急増は、5α-還元酵素欠損症市場を推進する主な要因になると予測されます。

遺伝性疾患や希少疾患の急増は、今後数年間の5α-還元酵素欠損症市場の成長軌道を推進する構えです。遺伝性疾患や希少疾患は、個人の遺伝子の変化から発生し、一般集団ではまれな疾患であるため、人間の開発、特に5α-還元酵素欠損症に代表される性分化に関する遺伝的要因の複雑な役割を浮き彫りにしています。オーストラリア政府保健省が2022年11月に指摘したように、致死的または重度障害となる約7,000の希少疾病が存在します。これらの希少疾患は、オーストラリア国民の約8％、合計約200万人に影響を与え、その約80％は遺伝的なものです。従って、遺伝性疾患や希少疾患の蔓延は、5α-還元酵素欠損症市場を推進する極めて重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の5α-還元酵素欠損症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の5α-還元酵素欠損症市場：成長率分析
• 世界の5α-還元酵素欠損症市場の実績：規模と成長, 2019-2024
• 世界の5α-還元酵素欠損症市場の予測：規模と成長, 2024-2029, 2034F
• 世界の5α-還元酵素欠損症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の5α-還元酵素欠損症市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 染色体分析
• 遺伝子配列解析
• ホルモン検査
• 画像検査
• 遺伝子検査
• その他の診断
• 世界の5α-還元酵素欠損症市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 膣形成術
• 女性化性器形成術
• ホルモン補充療法
• その他の治療
• 世界の5α-還元酵素欠損症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の5α-還元酵素欠損症市場：染色体分析のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 核型分析
• 蛍光in situハイブリダイゼーション（FISH）
• 世界の5α-還元酵素欠損症市場：遺伝子配列のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的遺伝子パネル
• 全エクソーム配列解析
• 世界の5α-還元酵素欠損症市場：ホルモン検査のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テストステロンレベル
• ジヒドロテストステロン（DHT）レベル
• 世界の5α-還元酵素欠損症市場：画像検査のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 超音波
• MRI
• 世界の5α-還元酵素欠損症市場：遺伝子検査のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• キャリアテスト
• 新生児スクリーニング
• 世界の5α-還元酵素欠損症市場：その他の診断のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床評価
• 家族歴評価

第7章 地域別・国別分析

• 世界の5α-還元酵素欠損症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の5α-還元酵素欠損症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 5α-還元酵素欠損症市場：競合情勢
• 5α-還元酵素欠損症市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Eli Lilly and Company
• Alma Lasers Ltd.
• Viveve Medical Inc.
• Fotona d.o.o
• Almirall SA
• Hologic Inc.
• Gilead Sciences Inc.
• Johnson & Johnson Services Inc.
• Mallinckrodt Pharmaceuticals
• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• Roivant Sciences Ltd.
• Sanofi Genzyme
• Shionogi & Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 5α-還元酵素欠損症市場2029：新たな機会を提供する国
• 5α-還元酵素欠損症市場2029：新たな機会を提供するセグメント
• 5α-還元酵素欠損症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

5-alpha reductase deficiency is a disorder that impacts male sexual development, both preceding and during puberty. Individuals with this condition experience insufficient production of dihydrotestosterone, a crucial hormone for male sexual development.

The primary diagnostic methods for 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, and genetic screening, among others. Chromosome analysis is employed to determine the patient's chromosomal makeup, distinguishing between XX (Female) and XY (Male) chromosomes. Various treatments are available for 5-alpha reductase deficiency, including surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and other interventions. End-users of these treatments include hospitals, specialty clinics, and other medical facilities.

The 5-alpha reductase deficiency market research report is one of a series of new reports from The Business Research Company that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to research and development, regulatory landscape, healthcare infrastructure, increased awareness and education, health insurance coverage.

The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to innovations in therapeutics, genetic research advances, precision medicine, global health initiatives, integration of gene therapies. Major trends in the forecast period include advancements in treatment options, diagnostic innovations, patient-centric approaches, regulatory landscape, market access and affordability.

The escalating number of research and development endeavors in genomics is significantly contributing to the growth trajectory of the 5-alpha reductase deficiency market. Genomics, involving the comprehensive study of an individual's entire genome, including the interplay between genes and their environment, serves as a pivotal tool in diagnosing 5-alpha reductase deficiency by pinpointing specific genetic mutations responsible for the condition. Consequently, the surge in research and development activities within genomics is poised to play a crucial role in not only uncovering but also treating this disorder. As detailed in the 'Accelerating Access to Genomics for Global Health' report by the World Health Organization (WHO) in July 2022, the percentage of nations equipped to perform genomic surveillance surged from 54% to 68% between March 2021 and January 2022. Therefore, the burgeoning research and development efforts in genomics are forecasted to be a primary driver propelling the 5-alpha reductase deficiency market.

The mounting prevalence of genetic and rare diseases stands poised to propel the growth trajectory of the 5-alpha reductase deficiency market in the forthcoming years. Genetic and rare diseases, arising from alterations in an individual's genes and being uncommon within the general populace, highlight the intricate role of genetic factors in human development, especially concerning sexual differentiation, exemplified by 5-alpha reductase deficiency. As noted in November 2022 by the Australian Government Department of Health, approximately 7,000 rare illnesses, either fatal or severely disabling, exist. These rare diseases impact about 8% of Australians, totaling around 2 million individuals, with roughly 80% being genetic in nature. Consequently, the escalating prevalence of genetic and rare diseases constitutes a pivotal factor propelling the 5-alpha reductase deficiency market.

The emergence of innovative genetic testing methodologies for diagnosing rare diseases constitutes a key trend in the 5-alpha reductase deficiency market. Leading entities operating within this domain are directing their efforts toward developing pioneering genetic testing solutions that efficiently diagnose rare conditions such as 5-alpha reductase deficiency, particularly in their nascent stages. These advancements in diagnostics not only offer a competitive advantage to major market players but also enhance their position in the market. For instance, in June 2022, Avesthagen Limited, a US-based integrated systems biology platform company, unveiled its latest genetic testing portfolio. The genome panels encompassed in this portfolio present highly specialized, disease-centric analyses tailored for rare genetic diseases, thereby showcasing significant strides in the diagnostic landscape.

Leading companies in the 5-alpha reductase deficiency market are focusing on the development of advanced products, such as consumer-initiated genetic tests, enabling individuals to access personal genetic information privately and directly, without requiring a healthcare provider's referral. A consumer-initiated genetic test allows individuals to order genetic testing from a laboratory or testing company independently, providing insights into genetic predispositions, ancestry, or health-related traits without the need for a healthcare provider's involvement. For example, in July 2023, Quest Diagnostics, a US-based diagnostic information services provider, introduced Genetic Insights, a consumer-initiated genetic test. This new product helps individuals evaluate their risk of developing certain hereditary health conditions. It offers advanced technology, personalized health reports, and access to genetic counseling. By analyzing a saliva sample, Genetic Insights assesses 36 genes to identify risks for nearly two dozen hereditary conditions, including breast and colon cancer, heart and blood disorders, and carrier status for conditions such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test is designed to address gaps in existing consumer genetic tests and utilizes state-of-the-art next-generation sequencing (NGS) technology, which can analyze thousands of DNA variants in disease-related genes and examines more regions of a person's genome compared to traditional microarray testing.

In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical firm, completed the acquisition of ENTADFI (finasteride/tadalafil) from Veru Inc. for an approximate sum of $100 million. This acquisition significantly expands the company's scope across various pharmaceutical sectors. By acquiring ENTADFI, Blue Water gains entry into the commercial domain while also mitigating expenditure and securing crucial revenue streams for the vaccine candidate pipeline. Despite this expansion, Blue Water remains steadfast in its primary mission of aiding individuals in need and is eager to enhance this asset and the pipeline for patients worldwide. Veru Inc. functions as a US-based biopharmaceutical company.

Major companies operating in the 5-alpha reductase deficiency market include F. Hoffmann-La Roche Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Alma Lasers Ltd., Viveve Medical Inc., Fotona d.o.o, Almirall SA, Hologic Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Roivant Sciences Ltd., Sanofi Genzyme, Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zoetis Inc., Cadila Healthcare Limited, Endo International plc

North America was the largest region in the 5-alpha reductase deficiency market in 2024. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The 5-alpha reductase deficiency market includes revenues earned by entities by providing ultrasound screening diagnosis and surgical procedures to treat 5-alpha reductase deficiencies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

5-Alpha Reductase Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on 5-alpha reductase deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for 5-alpha reductase deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The 5-alpha reductase deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis: Chromosome Analysis; Gene Sequencing; Hormone Tests; Imaging Tests; Genetic Screening; Other Diagnosis
• 2) By Treatment: Surgery; Vaginoplasty; Feminizing Genitoplasty; Hormone Replacement Therapy; Other Treatments
• 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Chromosome Analysis: Karyotyping; Fluorescence In Situ Hybridization (FISH)
• 2) By Gene Sequencing: Targeted Gene Panels; Whole Exome Sequencing
• 3) By Hormone Tests: Testosterone Levels; Dihydrotestosterone (DHT) Levels
• 4) By Imaging Tests: Ultrasound; MRI
• 5) By Genetic Screening: Carrier Testing; Newborn Screening
• 6) By Other Diagnosis: Clinical Evaluation; Family History Assessment
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi SA; Pfizer Inc.; GlaxoSmithKline plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. 5-Alpha Reductase Deficiency Market Characteristics

3. 5-Alpha Reductase Deficiency Market Trends And Strategies

4. 5-Alpha Reductase Deficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global 5-Alpha Reductase Deficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global 5-Alpha Reductase Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global 5-Alpha Reductase Deficiency Market Growth Rate Analysis
• 5.4. Global 5-Alpha Reductase Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global 5-Alpha Reductase Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global 5-Alpha Reductase Deficiency Total Addressable Market (TAM)

6. 5-Alpha Reductase Deficiency Market Segmentation

• 6.1. Global 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chromosome Analysis
• Gene Sequencing
• Hormone Tests
• Imaging Tests
• Genetic Screening
• Other Diagnosis
• 6.2. Global 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Vaginoplasty
• Feminizing Genitoplasty
• Hormone Replacement Therapy
• Other Treatments
• 6.3. Global 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.4. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Chromosome Analysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Karyotyping
• Fluorescence In Situ Hybridization (FISH)
• 6.5. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Gene Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Gene Panels
• Whole Exome Sequencing
• 6.6. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Hormone Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testosterone Levels
• Dihydrotestosterone (DHT) Levels
• 6.7. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Imaging Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ultrasound
• MRI
• 6.8. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Genetic Screening, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carrier Testing
• Newborn Screening
• 6.9. Global 5-Alpha Reductase Deficiency Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Evaluation
• Family History Assessment

7. 5-Alpha Reductase Deficiency Market Regional And Country Analysis

• 7.1. Global 5-Alpha Reductase Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global 5-Alpha Reductase Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific 5-Alpha Reductase Deficiency Market

• 8.1. Asia-Pacific 5-Alpha Reductase Deficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China 5-Alpha Reductase Deficiency Market

• 9.1. China 5-Alpha Reductase Deficiency Market Overview
• 9.2. China 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India 5-Alpha Reductase Deficiency Market

• 10.1. India 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan 5-Alpha Reductase Deficiency Market

• 11.1. Japan 5-Alpha Reductase Deficiency Market Overview
• 11.2. Japan 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia 5-Alpha Reductase Deficiency Market

• 12.1. Australia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia 5-Alpha Reductase Deficiency Market

• 13.1. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea 5-Alpha Reductase Deficiency Market

• 14.1. South Korea 5-Alpha Reductase Deficiency Market Overview
• 14.2. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe 5-Alpha Reductase Deficiency Market

• 15.1. Western Europe 5-Alpha Reductase Deficiency Market Overview
• 15.2. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK 5-Alpha Reductase Deficiency Market

• 16.1. UK 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany 5-Alpha Reductase Deficiency Market

• 17.1. Germany 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France 5-Alpha Reductase Deficiency Market

• 18.1. France 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy 5-Alpha Reductase Deficiency Market

• 19.1. Italy 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain 5-Alpha Reductase Deficiency Market

• 20.1. Spain 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe 5-Alpha Reductase Deficiency Market

• 21.1. Eastern Europe 5-Alpha Reductase Deficiency Market Overview
• 21.2. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia 5-Alpha Reductase Deficiency Market

• 22.1. Russia 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America 5-Alpha Reductase Deficiency Market

• 23.1. North America 5-Alpha Reductase Deficiency Market Overview
• 23.2. North America 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA 5-Alpha Reductase Deficiency Market

• 24.1. USA 5-Alpha Reductase Deficiency Market Overview
• 24.2. USA 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada 5-Alpha Reductase Deficiency Market

• 25.1. Canada 5-Alpha Reductase Deficiency Market Overview
• 25.2. Canada 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America 5-Alpha Reductase Deficiency Market

• 26.1. South America 5-Alpha Reductase Deficiency Market Overview
• 26.2. South America 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil 5-Alpha Reductase Deficiency Market

• 27.1. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East 5-Alpha Reductase Deficiency Market

• 28.1. Middle East 5-Alpha Reductase Deficiency Market Overview
• 28.2. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa 5-Alpha Reductase Deficiency Market

• 29.1. Africa 5-Alpha Reductase Deficiency Market Overview
• 29.2. Africa 5-Alpha Reductase Deficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa 5-Alpha Reductase Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa 5-Alpha Reductase Deficiency Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. 5-Alpha Reductase Deficiency Market Competitive Landscape And Company Profiles

• 30.1. 5-Alpha Reductase Deficiency Market Competitive Landscape
• 30.2. 5-Alpha Reductase Deficiency Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. 5-Alpha Reductase Deficiency Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Eli Lilly and Company
• 31.3. Alma Lasers Ltd.
• 31.4. Viveve Medical Inc.
• 31.5. Fotona d.o.o
• 31.6. Almirall SA
• 31.7. Hologic Inc.
• 31.8. Gilead Sciences Inc.
• 31.9. Johnson & Johnson Services Inc.
• 31.10. Mallinckrodt Pharmaceuticals
• 31.11. Novo Nordisk A/S
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Roivant Sciences Ltd.
• 31.14. Sanofi Genzyme
• 31.15. Shionogi & Co. Ltd.

32. Global 5-Alpha Reductase Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The 5-Alpha Reductase Deficiency Market

34. Recent Developments In The 5-Alpha Reductase Deficiency Market

35. 5-Alpha Reductase Deficiency Market High Potential Countries, Segments and Strategies

• 35.1 5-Alpha Reductase Deficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 5-Alpha Reductase Deficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 5-Alpha Reductase Deficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer